Sun Pharmaceutical Industries Ltd. is India’s largest pharmaceutical company and a global leader in generic and specialty medicines. Headquartered in Mumbai, it operates across 100+ countries with a diversified portfolio spanning dermatology, ophthalmology, oncology, neurology, and complex injectables. With strong R&D capabilities, a robust pipeline, and leadership in the US generics market, Sun Pharma remains a cornerstone holding for long-term investors seeking exposure to India’s healthcare and export-driven pharma sector. As of January 2026, the company is delivering steady profit growth, maintaining healthy margins, and trading at a premium valuation reflective of its quality. This article provides a data-driven outlook on the Sun Pharma share price target 2026–2030.
Sun Pharmaceutical Industries: Company Overview
- Founded: 1983
- Managing Director: Mr. Dilip S. Shanghvi
- NSE Symbol: SUNPHARMA
- Key Segments: Generics (75%), Specialty (20%), APIs & Others (5%)
- Global Presence: Operations in 100+ countries; #1 in India, Top 5 in US generics
Sun Pharma’s strategic focus includes complex generics, dermatology (via subsidiary Taro), and biosimilars. The company has successfully integrated Ranbaxy (merged in 2015) and continues to deleverage its balance sheet while investing in innovation.
Sun Pharma: Key Financial Snapshot
| Metric | Value |
|---|---|
| Current Share Price | ₹1,670 |
| Market Capitalization | ₹4,00,496.99 Cr |
| No. of Shares Outstanding | 239.93 Cr |
| 52-Week High / Low | ₹1,910 / ₹1,547 |
| P/E Ratio (TTM) | 38.33 |
| P/B Ratio | 5.15 |
| EPS (TTM) | ₹43.55 |
| Book Value (TTM) | ₹324.34 |
| ROE | 16.16% |
| ROCE | 19.89% |
| Dividend Yield | 0.96% |
| Face Value | ₹1 |
| Cash | ₹5,770.29 Cr |
| Debt | ₹6,197.88 Cr |
| Sales Growth (YoY) | 8.42% |
| Profit Growth (YoY) | 13.80% |
| Promoter Holding | 54.48% |
Sun Pharma Share Price Target Forecast (2026–2030)
| Year | Target Price Range (₹) |
|---|---|
| 2026 | ₹1,760 – ₹1,920 |
| 2027 | ₹1,880 – ₹2,080 |
| 2028 | ₹2,000 – ₹2,250 |
| 2029 | ₹2,120 – ₹2,430 |
| 2030 | ₹2,240 – ₹2,620 |
Sun Pharma Share Price Target 2026
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2026 | ₹1,760 | ₹1,920 |
Sun Pharma reported 13.80% YoY profit growth in FY2025, supported by strong performance in the US and emerging markets. Its OPM stands at ~30%, and net debt is minimal (Debt/Equity: 0.07). Trading at a P/E of 38.33x—above the pharma sector average—the stock reflects investor confidence in its sustainable moat and global scale. A 2026 target range of ₹1,760–₹1,920 assumes continued pricing stability in the US and no major regulatory setbacks.
Sun Pharma Share Price Target 2027
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2027 | ₹1,880 | ₹2,080 |
If Sun Pharma sustains 10–12% earnings growth and benefits from new product launches (e.g., biosimilars, complex injectables), investor sentiment will remain strong. Assuming EPS reaches ₹46–₹49 by FY27 and P/E stabilizes at 39–40x, the 2027 target range of ₹1,880–₹2,080 is justified.
Sun Pharma Share Price Target 2028
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2028 | ₹2,000 | ₹2,250 |
By 2028, benefits from R&D investments and Taro’s dermatology dominance should reflect in margins. With ROCE of 19.89% and consistent cash flow, the company can support higher valuations. A P/E of 40–41x on projected EPS of ₹49–₹52 supports the ₹2,000–₹2,250 band.
Sun Pharma Share Price Target 2029
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2029 | ₹2,120 | ₹2,430 |
Long-term tailwinds include aging populations in the US/EU, India’s API push, and biosimilar adoption. If competition doesn’t erode pricing, EPS could reach ₹52–₹56 by FY29. At a P/E of 40–42x, the 2029 target is ₹2,120–₹2,430.
Sun Pharma Share Price Target 2030
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2030 | ₹2,240 | ₹2,620 |
Over a five-year horizon, Sun Pharma remains a high-quality compounder. If ROE holds above 16% and dividends continue (~35% payout), investor confidence will remain robust. A terminal P/E of 41–43x on FY30 EPS (~₹55–₹61) justifies the ₹2,240–₹2,620 range.
Sun Pharma: Shareholding Pattern
| Category | Holding (%) |
|---|---|
| Promoters | 54.48% |
| Domestic Institutional Investors (DII) | 20.81% |
| Foreign Institutional Investors (FII) | 16.12% |
| Public & Others | 8.58% |
High promoter holding ensures strategic continuity. Strong institutional ownership (36.93%) reflects analyst coverage and liquidity.
Sun Pharma: Strengths vs Risks
Strengths:
- Debt-free balance sheet (Net Cash: ₹5,770 Cr)
- Industry-leading ROCE (19.89%) and consistent 16%+ ROE
- Global scale with #1 position in the Indian pharma
- Strong dividend track record (33–35% payout)
Risks:
- High P/E leaves little room for execution misses
- US FDA compliance risks (historical Ranbaxy legacy)
- Intense competition in the generic space
- Currency volatility (70%+ revenue in USD)
Investment Suitability
| Factor | Assessment |
|---|---|
| Risk Profile | Moderate |
| Ideal Time Horizon | 5+ years |
| Volatility | Lower than market average |
| Dividend/Income Potential | Moderate (0.96% yield + consistent payouts) |
| Best For | Core portfolio holding for investors seeking quality healthcare exposure |
FAQs
Is Sun Pharma listed?
Yes. Sun Pharmaceutical Industries is listed on both the NSE (SUNPHARMA) and BSE (524715).
What is the price target of Sun Pharma in 2026?
Based on fundamentals, the Sun Pharma share price target for 2026 is ₹1,760–₹1,920.
Which company merged with Sun Pharma?
Sun Pharma acquired Ranbaxy Laboratories in 2015 in a landmark $4 billion deal—one of India’s largest cross-border acquisitions.
What is the profit of Sun Pharma in 2025?
For FY2025, Sun Pharma reported a net profit of ₹10,485 crore, up 13.8% YoY, with EPS of ₹43.55.
Is it good to invest in Sun Pharma?
Yes—for long-term portfolios. Despite its premium valuation (P/E: 38x), Sun Pharma offers unmatched scale, profitability, and global presence in pharma. Suitable as a core holding, not a speculative bet.
Final Verdict
Sun Pharmaceutical Industries remains India’s pharma crown jewel—profitable, cash-rich, and globally competitive. While not cheap, its quality justifies a premium.
Our Sun Pharma share price target 2026–2030 (₹1,760 to ₹2,620) reflects steady earnings growth, moderate multiple expansion, and sustained investor confidence. It won’t deliver explosive gains, but offers reliable compounding for those betting on India’s healthcare leadership.
Disclaimer: Price targets are estimates based on publicly available data and sector analysis. They are not investment advice. Consult a SEBI-registered advisor before making decisions.
Sources
- Screener.in – Sun Pharma Consolidated Page (FY2025 + TTM)
- Finology Ticker – SUNPHARMA Financials & Analysis
- Groww.in – Sun Pharma Stock Profile
- Sun Pharma Investor Presentation (Q3 FY26, Jan 2026)
- US FDA & TRAI Guidelines on Pharma Compliance
